{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:51:19Z","timestamp":1793998279372,"version":"4.8.0"},"reference-count":129,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100007325","name":"American Association of Physicists in Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007325","name":"American Association of Physicists in Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare calcitonin gene\u2013related peptide monoclonal antibodies (CGRP mAbs) versus nonspecific oral migraine preventives (NOEPs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Insurers mandate step therapy with NOEPs before approving CGRP mAbs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Databases were searched for class I or II randomized controlled trials (RCTs) comparing CGRP mAbs or NOEPs versus placebo for migraine prevention in adults. The primary outcome measure was monthly migraine days (MMD) or moderate to severe headache days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twelve RCTs for CGRP mAbs, 5 RCTs for topiramate, and 3 RCTs for divalproex were included in the meta\u2010analysis. There was high certainty that CGRP mAbs are more effective than placebo, with weighted mean difference (WMD; 95% confidence interval) of \u22121.64 (\u22121.99 to \u22121.28) MMD, which is compatible with small effect size (Cohen's\n                      <jats:italic>d<\/jats:italic>\n                      \u22120.25 [\u22120.34 to \u22120.16]). Certainty of evidence that topiramate or divalproex is more effective than placebo was very low and low, respectively (WMD \u22121.45 [\u22121.52 to \u22121.38] and \u22121.65 [\u22122.30 to \u22121.00], respectively; Cohen's\n                      <jats:italic>d<\/jats:italic>\n                      \u22121.25 [\u22122.47 to \u22120.03] and \u22120.48 [\u22120.67 to \u22120.29], respectively). Trial sequential analysis showed that information size was adequate and that CGRP mAbs had clear benefit versus placebo. Network meta\u2010analysis showed no statistically significant difference between CGRP mAbs and topiramate (WMD \u22120.19 [\u22120.56 to 0.17]) or divalproex (0.01 [\u22120.73 to 0.75]). No significant difference was seen between topiramate or divalproex (0.21 [\u22120.45 to 0.86]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>There is high certainty that CGRP mAbs are more effective than placebo, but the effect size is small. When feasible, CGRP mAbs may be prescribed as first\u2010line preventives; topiramate or divalproex could be as effective but are less well tolerated. The findings of this study support the recently published 2024 position of the American Headache Society on the use of CGRP mAbs as the first\u2010line treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14693","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T07:04:38Z","timestamp":1713423878000},"page":"547-572","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nonspecific oral medications versus anti\u2013calcitonin gene\u2010related peptide monoclonal antibodies for migraine: A\u00a0systematic review and meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-1125","authenticated-orcid":false,"given":"Jennifer","family":"Robblee","sequence":"first","affiliation":[{"name":"Department of Neurology, Barrow Neurological Institute St. Joseph's Hospital and Medical Center  Phoenix Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1900-0353","authenticated-orcid":false,"given":"Sameh M.","family":"Hakim","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Intensive Care, and Pain Management Ain Shams University Faculty of Medicine  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6744-3517","authenticated-orcid":false,"given":"John M.","family":"Reynolds","sequence":"additional","affiliation":[{"name":"The Louis Calder Memorial Library University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-252X","authenticated-orcid":false,"given":"Teshamae S.","family":"Monteith","sequence":"additional","affiliation":[{"name":"Division of Headache, Department of Neurology University of Miami Miller School of Medicine  Miami Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niushen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology &amp; Neurological Sciences Stanford Health Care  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3182-7030","authenticated-orcid":false,"given":"Meredith","family":"Barad","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Perioperative and Pain Medicine Stanford Health Care  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02185.x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_11_4_1","unstructured":"UnitedHealthcare Clinical Pharmacy Programs.Prior Authorization\/Medical Necessity Program: Aimovig (erenumab) Ajovy (fremanezumab)* Emgality (galcanezumab) 2023."},{"key":"e_1_2_11_5_1","unstructured":"Cigna Drug and Biologic Coverage Policy.Calcitonin Gene\u2010Related Peptide (CGRP) Inhibitors \u2013 Preventative Migraine Treatment for Individual and Family Plans 2021."},{"key":"e_1_2_11_6_1","volume-title":"2017 Edition Clinical Practice Guideline Process Manual","author":"Gary S","year":"2017"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420941839"},{"key":"e_1_2_11_9_1","volume-title":"Drug Treatments for the Prevention of Migraine Headache","author":"Gray RN","year":"1999"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.6.754"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102414547138"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418801579"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13498"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00757.x"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-0998-8"},{"key":"e_1_2_11_16_1","volume-title":"Finding What Works in Health Care: Standards for Systematic Reviews","author":"Institute of Medicine (US) Committee on Standards for Systematic Reviews of Comparative Effectiveness Research","year":"2011"},{"key":"e_1_2_11_17_1","volume-title":"Randomised Controlled Trials: CINAHL for Ebsco","author":"Clowes M","year":"2019"},{"key":"e_1_2_11_18_1","unstructured":"BMJ Best Practice.Study Design Search Filters."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1348\/000711299160220"},{"key":"e_1_2_11_20_1","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"Wong SS","year":"2006","journal-title":"J Med Libr Assoc"},{"key":"e_1_2_11_21_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins JPT","year":"2022"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2001.01156.x"},{"key":"e_1_2_11_25_1","volume-title":"The Capital Region, Copenhagen University Hospital \u2010 Rigshospitalet: The Copenhagen Trial Unit","author":"Trial Sequential Analysis (TSA) software","year":"2021"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/XEB.0000000000000141"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530245"},{"key":"e_1_2_11_29_1","first-page":"1135","article-title":"Applying the law of the iterated logarithm to cumulative meta\u2010analysis of a continuous endpoint","volume":"13","author":"Lan KK","year":"2003","journal-title":"Stat Sin"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(97)00049-8"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.36.4.684"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01800.x"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540080036010"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1987.00520170016015"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.05.025"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.03.020"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2004.03.004"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2022.107151"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1983.hed2304188.x"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1987.hed2707372.x"},{"key":"e_1_2_11_41_1","first-page":"37","article-title":"Comparative trial of Tenormin (atenolol) and Inderal (propranolol) in migraine","volume":"31","author":"Stensrud P","year":"1980","journal-title":"Ups J Med Sci Suppl"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1983.0304207.x"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1987.0704231.x"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2524.1988.hed2801015.x"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01377.x"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1984.0402091.x"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1984.tb00815.x"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1983.hed2301026.x"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1515\/jom-1984-841214"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(84)90600-8"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1986.hed2610490.x"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1987.hed2708421.x"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.22.4.366"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1973.hed1204163.x"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1974.tb02810.x"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5921.699"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1976.hed1601024.x"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1976.hed1605238.x"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1976.tb04342.x"},{"key":"e_1_2_11_60_1","first-page":"273","article-title":"Propranolol and migraine. A clinical trial","volume":"3","author":"Pita E","year":"1977","journal-title":"Arch Farmacol Toxicol"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.1983.tb08456.x"},{"key":"e_1_2_11_62_1","first-page":"263","article-title":"Propranolol in prophylaxis of migraine","volume":"82","author":"Ahuja GK","year":"1985","journal-title":"Indian J Med Res"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024870070S6204"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024870070S6203"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1990.1002101.x"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1993.1302128.x"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1989.0904247.x"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550210071015"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1984.tb07772.x"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0464-6"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2008.01087.x"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211047454"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.1979.hed1907379.x"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03350180030025"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1992.1202081.x"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.4.647"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1995.00540270077022"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1702103.x"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.11.1652"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00413.x"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.3923\/ijp.2010.670.675"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.3109\/00207454.2011.626908"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.01190.x"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.8.965"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-004-0350-0"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.4.490"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.07.003"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2007.01326.x"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00684.x"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410372427"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211053571"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2005.05029.x"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14138"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709038"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.4853"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14178"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14169"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006640"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1212"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1962.00450210001001"},{"issue":"7","key":"e_1_2_11_106_1","first-page":"1","article-title":"Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society","volume":"8","author":"Headache Classification Committee of the International Headache Society","year":"1988","journal-title":"Cephalalgia"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.031286"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12196"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14051"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221143538"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13596"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13414"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14305"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnab236"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12774"},{"key":"e_1_2_11_117_1","volume-title":"Understanding Value\u2010Based Insurance Design","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12051"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1001\/amajethics.2021.639"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200220020-00002"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14053"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2018.1457533"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418796842"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01358-9"},{"key":"e_1_2_11_125_1","first-page":"645","article-title":"Changes in acute headache medication use and health care resource utilization: results from a randomized, double\u2010blind, placebo\u2010controlled clinical trial evaluating galcanezumab in adults with treatment\u2010resistant migraine (CONQUER)","volume":"28","author":"Ambrosini A","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-021-00319-z"},{"key":"e_1_2_11_127_1","unstructured":"Lilly Announces the Launch of TRIUMPH the First Long\u2010Term Real\u2010World Evidence Study of Emgality\u00ae (galcanezumab\u2010gnlm). In Cision PR Newswire.2019."},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01431-x"},{"key":"e_1_2_11_129_1","unstructured":"National Headache Foundation.National Headache Foundation Position Statement on the Treatment of Migraine.2022."},{"key":"e_1_2_11_130_1","doi-asserted-by":"crossref","unstructured":"CharlesAC DigreKB GoadsbyPJ RobbinsMS HersheyA.American Headache Society. Calcitonin gene\u2010related peptide\u2010targeting therapies are a first\u2010line option for the prevention of migraine: An American Headache Society position statement update. Headache.2024. doi:10.1111\/head.14692","DOI":"10.1111\/head.14692"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:20:37Z","timestamp":1762078837000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":129,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/head.14693"],"URL":"https:\/\/doi.org\/10.1111\/head.14693","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]},"assertion":[{"value":"2023-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}